Related references
Note: Only part of the references are listed.Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
Khayriyyah Mohd Hanafiah et al.
HEPATOLOGY (2013)
Expediting Drug Development - The FDA's New Breakthrough Therapy Designation
Rachel E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Current and Future Therapies for Hepatitis C Virus Infection
T. Jake Liang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cancer Therapy-Induced Cardiac Toxicity in Early Breast Cancer Addressing the Unresolved Issues
Michel G. Khouri et al.
CIRCULATION (2012)
The race for interferon-free HCV therapies: a snapshot by the spring of 2012
Erik De Clercq
REVIEWS IN MEDICAL VIROLOGY (2012)
INX-08189, a Phosphoramidate Prodrug of 6-O-Methyl-2′-C-Methyl Guanosine, Is a Potent Inhibitor of Hepatitis C Virus Replication with Excellent Pharmacokinetic and Pharmacodynamic Properties
John H. Vernachio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
A Twenty-Eight-Day Mechanistic Time Course Study in the Rhesus Monkey with Hepatitis C Virus Protease Inhibitor BILN 2061
James H. Stoltz et al.
TOXICOLOGIC PATHOLOGY (2011)
Diagnosis, Management, and Treatment of Hepatitis C: An Update
Marc G. Ghany et al.
HEPATOLOGY (2009)
The FDA critical path initiative and its influence on new drug development
Janet Woodcock et al.
ANNUAL REVIEW OF MEDICINE (2008)
Share Paper
